Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26764110 | 1.00 | SMN1; SMN2 (0.57) | SMN1; SMN2KMT2AMEN1NPC1RAB9A | |
| SCHEMBL24011327 | 0.89 | SMN1; SMN2 (0.58) | SMN1; SMN2KMT2AMEN1NPC1RAB9A | |
| SCHEMBL26633903 | 0.88 | NPC1 (0.59) | SMN1; SMN2KMT2AMEN1NPC1RAB9A | |
| SCHEMBL26764099 | 0.86 | SMN1; SMN2 (0.57) | SMN1; SMN2KMT2AMEN1NPC1RAB9A | |
| SCHEMBL30288103 | 0.85 | SMN1; SMN2 (0.47) | SMN1; SMN2NPC1RAB9ASCN9AALDH1A1 | |
| SCHEMBL26764123 | 0.85 | SMN1; SMN2 (0.47) | SMN1; SMN2NPC1RAB9ASCN9AALDH1A1 | |
| SCHEMBL30306659 | 0.84 | NPSR1 (0.56) | SMN1; SMN2KMT2ANPC1RAB9AGAA | |
| SCHEMBL26764097 | 0.84 | NPSR1 (0.56) | SMN1; SMN2KMT2ANPC1RAB9AGAA | |
| SCHEMBL26633908 | 0.83 | MCHR1 (0.47) | SMN1; SMN2KMT2AMEN1NPC1RAB9A | |
| SCHEMBL26633708 | 0.82 | NPC1 (0.55) | SMN1; SMN2KMT2AMEN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115843295-B | NAMPT modulators | 赛特凯恩蒂克公司 | 2025-04-15 | — | — | CN | disclosed |
| US-20230348369-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-11-02 | — | — | US | disclosed |
| CN-115843295-A | NAMPT modulators | 赛特凯恩蒂克公司 | 2023-03-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348369-A1 | NAMPT MODULATORS | NAMPT, NNT, NAPRT | SMN1; SMN2 610/4885KMT2A 1973/4885MEN1 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.